Table 2.
Plasma levels of tested parameters prior to and post to surgical treatment of breast cancer patients.
| CXCL1 [pg/mL] Median (Q1–Q3) |
CXCL8 [pg/mL] Median (Q1–Q3) |
CA 15-3 [IU/mL] Median (Q1–Q3) |
|
|---|---|---|---|
| BC—total group (n = 43) | |||
| Before surgery | 32.606 (25.963–54.763) |
7.261 (3.807–11.115) |
18.2 (13.95–26.9) |
| After surgery (4–6 weeks) | 40.254 (31.305–55.098) |
7.313 (3.853–12.556) |
17.8 (12.9–20.0) |
| p | 0.059 | 0.443 | 0.029 |
| BC—Luminal A subgroup (n = 22) | |||
| Before surgery | 30.832(20.236–46.467) | 5.326 (1.77–8.846) |
18.25 (13.675–28.125) |
| After surgery (4–6 weeks) | 41.414 (32.966–52.634) |
7.229 (4.729–11.593) |
18.100 (13.975–19.3) |
| p | 0.048 | 0.023 | 0.153 |
| BC—Luminal B subgroup (n = 21) | |||
| Before surgery | 33.868 (27.363–57.562) |
10.043 (5.153–12.286) |
18.2 (14.6–25.9) |
| After surgery (4–6 weeks) | 37.061 (29.965–81.177) |
7.508 (2.73–12.579) |
15.6 (12.4–20.1) |
| p | 0.532 | 0.509 | 0.063 |